Cedars-Sinai Cancer | Strategic Alliance Partners

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Karen L. Reckamp, MD, MS, provides insight on how she is navigating challenges posed by the COVID-19 crisis.

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

Karen Reckamp, MD, MS, highlights the different agents that have been developed to target rarer abnormalities in non–small cell lung cancer.

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.